Therapies for Children With Autism Spectrum Disorders

62. Dosman CF, Drmic IE, Brian JA, et al.
Ferritin as an indicator of suspected iron
deficiency in children with autism spectrum
disorder: prevalence of low serum ferritin
concentration. Dev Med Child Neurol. 2006
Dec;48(12):1008-1009.
63. Schneider CK, Melmed RD, Barstow LE, et
al. Oral human immunoglobulin for children
with autism and gastrointestinal dysfunction:
a prospective, open-label study. J Autism
Dev Disord. 2006 Nov;36(8):1053-1064.
64. Handen BL, Melmed RD, Hansen RL, et al.
A double-blind, placebo-controlled trial of
oral human immunoglobulin for
gastrointestinal dysfunction in children with
autistic disorder. J Autism Dev Disord. 2009
May;39(5):796-805.
65. Nye C and Brice A. Combined vitamin B6magnesium
treatment in autism spectrum
disorder. Cochrane Database Syst Rev.
2005(4):CD003497.
66. Gaby AR. Natural approaches to epilepsy.
Altern Med Rev. 2007 Mar;12(1):9-24.
67. Pearl PL and Gibson KM. Clinical aspects
of the disorders of GABA metabolism in
children. Curr Opin Neurol. 2004
Apr;17(2):107-113.
68. Rossignol DA. Novel and emerging
treatments for autism spectrum disorders: a
systematic review. Ann Clin Psychiatry.
2009 Oct-Dec;21(4):213-236.
69. Lakhan SE and Vieira KF. Nutritional
therapies for mental disorders. Nutr J.
2008;7:2.
70. Levy R and Cooper P. Ketogenic diet for
epilepsy. Cochrane Database Syst Rev.
2003(3):CD001903.
71. Lechin F, van der Dijs B, Pardey-
Maldonado B, et al. Effects of amantadine
on circulating neurotransmitters in healthy
subjects. J Neural Transm. 2010
Mar;117(3):293-299.
72. Farlow MR. Treatment of mild cognitive
impairment (MCI). Curr Alzheimer Res.
2009 Aug;6(4):362-367.
73. Calvert JW, Cahill J and Zhang JH.
Hyperbaric oxygen and cerebral physiology.
Neurol Res. 2007 Mar;29(2):132-141.
131
74. McDonagh MS, Morgan D, Carson S, et al.
Systematic review of hyperbaric oxygen
therapy for cerebral palsy: the state of the
evidence. Dev Med Child Neurol. 2007
Dec;49(12):942-947.
75. Santoro A, Siviero P, Minicuci N, et al.
Effects of donepezil, galantamine and
rivastigmine in 938 italian patients with
Alzheimer’s disease: a prospective,
observational study. CNS Drugs. 2010 Feb
1;24(2):163-176.
76. Bradberry S and Vale A.
Dimercaptosuccinic acid (succimer; DMSA)
in inorganic lead poisoning. Clin Toxicol
(Phila). 2009 Aug;47(7):617-631.
77. Boscolo M, Antonucci S, Volpe AR, et al.
Acute mercury intoxication and use of
chelating agents. J Biol Regul Homeost
Agents. 2009 Oct-Dec;23(4):217-223.
78. Kidd PM. Autism, an extreme challenge to
integrative medicine. Part 2: medical
management. Altern Med Rev. 2002
Dec;7(6):472-99.
79. Gupta S. Immunological treatments for
autism. J Autism Dev Disord. 2000
Oct;30(5):475-479.
80. Yoder PJ, Warren SF, Kim K, et al.
Facilitating prelinguistic communication
skills in young children with developmental
delay. II: Systematic replication and
extension. J Speech Hear Res. 1994
Aug;37(4):841-851.
81. Warren SF, Yoder PJ, Gazdag GE, et al.
Facilitating prelinguistic communication
skills in young children with developmental
delay. J Speech Hear Res. 1993
Feb;36(1):83-97.
82. Bondy AS and Frost LA. PECS: The Picture
Exchange Communication System Training
Manual. 1st ed. Cherry Hill, NJ; 1994.
83. Baron-Cohen S, Ashwin E, Ashwin C, et al.
Talent in autism: hyper-systemizing, hyperattention
to detail and sensory
hypersensitivity. Philos Trans R Soc Lond B
Biol Sci. 2009 May 27;364(1522):1377-
1383.
84. Rogers SJ and Ozonoff S. Annotation: what
do we know about sensory dysfunction in
autism? A critical review of the empirical
evidence. J Child Psychol Psychiatry. 2005
Dec;46(12):1255-1268.